CG
ANIK icon

Cutler Group’s Anika Therapeutics ANIK Stock Holding History

Cutler Group’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-5,538
Closed -$182K – 4328
2020
Q1 		$160K Buy
5,538
+3,104
+128% +$126K 0.01% 1083
2019
Q4 		$126K Buy
2,434
+1,934
+387% +$112K 0.01% 1076
2019
Q3 		$27K Buy
+500
New +$25.7K ﹤0.01% 1956
2017
Q4 		– Sell
-1,000
Closed -$58K – 4824
2017
Q3 		$58K Buy
+1,000
New +$52.3K ﹤0.01% 2107
2017
Q1 		– Sell
-2,192
Closed -$105K – 6300
2016
Q4 		$107K Buy
2,192
+1,992
+996% +$92.1K ﹤0.01% 1848
2016
Q3 		$9K Buy
+200
New +$9.88K ﹤0.01% 4286
2016
Q2 		– Sell
-1,449
Closed -$68.3K – 6579
2016
Q1 		$64K Sell
1,449
-1,000
-41% -$40.6K ﹤0.01% 2059
2015
Q4 		$93K Buy
+2,449
New +$93.7K 0.01% 1840

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Cutler Group's ANIK Position: Q2 2020 in Review

Cutler Group sold out of Anika Therapeutics (ANIK) in Q2 2020, closing a stake of 5,538 shares — an estimated $182K sold.

Cutler Group first reported a position in ANIK in Q4 2015 and held it in 8 quarters. The position peaked at $160K in Q1 2020. 158 funds tracked by Wall St. Rank hold ANIK as of Q2 2020.

  • Cutler Group reported no remaining Anika Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Cutler Group sold 5,538 Anika Therapeutics shares in Q2 2020, an estimated $182K.
  • Cutler Group first reported a position in Anika Therapeutics in Q4 2015 and held it in 8 quarters.
  • Cutler Group's Anika Therapeutics position peaked at $160K in Q1 2020.
  • 158 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2020.

Based on Cutler Group's 13F filing for Q2 2020, filed 22 Jul 2020.